Industry Research Reports
Home > Reports > Service & Software > Global Multi-cancer Early Detection (MCED) Tests Market Outlook, In‑Depth Analysis & Forecast to 2031
Global Multi-cancer Early Detection (MCED) Tests Market Outlook, In‑Depth Analysis & Forecast to 2031
Industry: Service & Software
Published Date: 2025-07-24
Pages: 174 Pages
Report ld: 4799019
Request Sample
Customized Report
- Description
- Table of Contents
- Table of Figures
- Related Reports
PDF Download
- Description
- Table of Contents
- Table of Figures
- Related Reports
- PDF Download
Multi-cancer Early Detection (MCED) Tests Market Size(US$)
CAGR 2025-2031
19.7%
Market Size,2031
USD 3,081
Million
Market Snapshot
Market Size in 2025 (Value)
US$ 1,047 million
Market Forecast in 2031(Value)
US$ 3,081 million
CAGR
19.7%
Years Considered
2020-2031
Base Year
2025
Forecast Period
2025-2031
Source: Secondary research, interviews with experts, and QYResearch analysis
The global Multi-cancer Early Detection (MCED) Tests market is projected to grow from US$ 875 million in 2024 to US$ 3081 million by 2031, at a CAGR of 19.7% (2025-2031), driven by critical product segments and diverse end‑use applications.
The Multiple Cancer Early Detection (MCED) test is a blood test designed to detect multiple cancer types early, potentially before symptoms appear. Often referred to as liquid biopsies, these tests identify cancer signatures by analyzing circulating tumor DNA (ctDNA) and other biomarkers in the blood. While still under evaluation, the MCED test has the potential to revolutionize cancer screening because it has the potential to detect cancers not covered by current screening methods and increase overall early detection rates.
From a downstream perspective, Medical Institutions accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
Multi-cancer Early Detection (MCED) Tests leading manufacturers including Guardant Health, Exact Sciences, Freenome, Epiginomics AG, Bio-techne, ThriveEarlier Detection, GRAIL, Inc., CellMax life, Berry Genomics, Singlera Genomics, etc., dominate supply; the top five capture approximately % of global revenue, with Guardant Health leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).
Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Multi-cancer Early Detection (MCED) Tests market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
MARKET SEGMENTATION
By Company
- Guardant Health
- Exact Sciences
- Freenome
- Epiginomics AG
- Bio-techne
- ThriveEarlier Detection
- GRAIL, Inc.
- CellMax life
- Berry Genomics
- Singlera Genomics
- Geneseeq
- BGI Genomics
- Burning Rock Biotech Limited
- New Horizon Health Limited
- Yeasen Bio
- Hangzhou Aoru Biotech
- Amoy Diagnostics Co., Ltd.
- Genetron Health
- AnchorDx
- Surexam Bio-Tech Co.,Ltd.
- HaploX
- HefeiLaierBiotechnologyCo.,Ltd
Consumption by Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Segment by Type
- ctDNA Detection
- CTC Detection
- Exosome Detection
Segment by Application
- Medical Institutions
- Physical Examination Centers
Segment by Category
- IVD（In Vitro Diagnostics）
- LDT (Laboratory Developed Test)
CHAPTER OUTLINE
Chapter 1: Defines the Multi-cancer Early Detection (MCED) Tests study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 14: Actionable conclusions and strategic recommendations.
WHY THIS REPORT
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
QYRESEARCH'S STRENGTHS
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:
Market entry risks/opportunities by region
We identify regional market threats and growth prospects to guide your overseas layout.
Product mix optimization based on local practices
We adjust product portfolios in line with local consumption habits.
Competitor tactics in fragmented vs. consolidated markets
We unpack rivals’ operation strategies for scattered and highly concentrated industries.
Full Research Coverage
We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.
19 Years Industry Expertise
We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.
24/7 Fast Report Delivery
Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.
Localized Strategic Analysis
We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.
Market entry risks/opportunities by region
All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.
Market entry risks/opportunities by region
We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.
TABLE OF CONTENTS
1 Study Coverage
1.1 Introduction to Multi-cancer Early Detection (MCED) Tests: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Multi-cancer Early Detection (MCED) Tests Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 ctDNA Detection
1.2.3 CTC Detection
1.2.4 Exosome Detection
1.3 Market Segmentation by Application
1.3.1 Global Multi-cancer Early Detection (MCED) Tests Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Medical Institutions
1.3.3 Physical Examination Centers
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Multi-cancer Early Detection (MCED) Tests Revenue Estimates and Forecasts 2020-2031
2.2 Global Multi-cancer Early Detection (MCED) Tests Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Multi-cancer Early Detection (MCED) Tests Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Multi-cancer Early Detection (MCED) Tests Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 ctDNA Detection Market Size by Players
3.3.2 CTC Detection Market Size by Players
3.3.3 Exosome Detection Market Size by Players
3.4 Global Multi-cancer Early Detection (MCED) Tests Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Multi-cancer Early Detection (MCED) Tests Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Multi-cancer Early Detection (MCED) Tests Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Multi-cancer Early Detection (MCED) Tests Market Size by Type (2020-2031)
6.4 North America Multi-cancer Early Detection (MCED) Tests Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Multi-cancer Early Detection (MCED) Tests Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Multi-cancer Early Detection (MCED) Tests Market Size by Type (2020-2031)
7.4 Europe Multi-cancer Early Detection (MCED) Tests Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Multi-cancer Early Detection (MCED) Tests Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Multi-cancer Early Detection (MCED) Tests Market Size by Type (2020-2031)
8.4 Asia-Pacific Multi-cancer Early Detection (MCED) Tests Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Multi-cancer Early Detection (MCED) Tests Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Multi-cancer Early Detection (MCED) Tests Market Size by Type (2020-2031)
9.4 Central and South America Multi-cancer Early Detection (MCED) Tests Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Multi-cancer Early Detection (MCED) Tests Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Multi-cancer Early Detection (MCED) Tests Market Size by Type (2020-2031)
10.4 Middle East and Africa Multi-cancer Early Detection (MCED) Tests Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Multi-cancer Early Detection (MCED) Tests Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Guardant Health
11.1.1 Guardant Health Corporation Information
11.1.2 Guardant Health Business Overview
11.1.3 Guardant Health Multi-cancer Early Detection (MCED) Tests Product Features and Attributes
11.1.4 Guardant Health Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (2020-2025)
11.1.5 Guardant Health Multi-cancer Early Detection (MCED) Tests Revenue by Product in 2024
11.1.6 Guardant Health Multi-cancer Early Detection (MCED) Tests Revenue by Application in 2024
11.1.7 Guardant Health Multi-cancer Early Detection (MCED) Tests Revenue by Geographic Area in 2024
11.1.8 Guardant Health Multi-cancer Early Detection (MCED) Tests SWOT Analysis
11.1.9 Guardant Health Recent Developments
11.2 Exact Sciences
11.2.1 Exact Sciences Corporation Information
11.2.2 Exact Sciences Business Overview
11.2.3 Exact Sciences Multi-cancer Early Detection (MCED) Tests Product Features and Attributes
11.2.4 Exact Sciences Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (2020-2025)
11.2.5 Exact Sciences Multi-cancer Early Detection (MCED) Tests Revenue by Product in 2024
11.2.6 Exact Sciences Multi-cancer Early Detection (MCED) Tests Revenue by Application in 2024
11.2.7 Exact Sciences Multi-cancer Early Detection (MCED) Tests Revenue by Geographic Area in 2024
11.2.8 Exact Sciences Multi-cancer Early Detection (MCED) Tests SWOT Analysis
11.2.9 Exact Sciences Recent Developments
11.3 Freenome
11.3.1 Freenome Corporation Information
11.3.2 Freenome Business Overview
11.3.3 Freenome Multi-cancer Early Detection (MCED) Tests Product Features and Attributes
11.3.4 Freenome Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (2020-2025)
11.3.5 Freenome Multi-cancer Early Detection (MCED) Tests Revenue by Product in 2024
11.3.6 Freenome Multi-cancer Early Detection (MCED) Tests Revenue by Application in 2024
11.3.7 Freenome Multi-cancer Early Detection (MCED) Tests Revenue by Geographic Area in 2024
11.3.8 Freenome Multi-cancer Early Detection (MCED) Tests SWOT Analysis
11.3.9 Freenome Recent Developments
11.4 Epiginomics AG
11.4.1 Epiginomics AG Corporation Information
11.4.2 Epiginomics AG Business Overview
11.4.3 Epiginomics AG Multi-cancer Early Detection (MCED) Tests Product Features and Attributes
11.4.4 Epiginomics AG Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (2020-2025)
11.4.5 Epiginomics AG Multi-cancer Early Detection (MCED) Tests Revenue by Product in 2024
11.4.6 Epiginomics AG Multi-cancer Early Detection (MCED) Tests Revenue by Application in 2024
11.4.7 Epiginomics AG Multi-cancer Early Detection (MCED) Tests Revenue by Geographic Area in 2024
11.4.8 Epiginomics AG Multi-cancer Early Detection (MCED) Tests SWOT Analysis
11.4.9 Epiginomics AG Recent Developments
11.5 Bio-techne
11.5.1 Bio-techne Corporation Information
11.5.2 Bio-techne Business Overview
11.5.3 Bio-techne Multi-cancer Early Detection (MCED) Tests Product Features and Attributes
11.5.4 Bio-techne Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (2020-2025)
11.5.5 Bio-techne Multi-cancer Early Detection (MCED) Tests Revenue by Product in 2024
11.5.6 Bio-techne Multi-cancer Early Detection (MCED) Tests Revenue by Application in 2024
11.5.7 Bio-techne Multi-cancer Early Detection (MCED) Tests Revenue by Geographic Area in 2024
11.5.8 Bio-techne Multi-cancer Early Detection (MCED) Tests SWOT Analysis
11.5.9 Bio-techne Recent Developments
11.6 ThriveEarlier Detection
11.6.1 ThriveEarlier Detection Corporation Information
11.6.2 ThriveEarlier Detection Business Overview
11.6.3 ThriveEarlier Detection Multi-cancer Early Detection (MCED) Tests Product Features and Attributes
11.6.4 ThriveEarlier Detection Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (2020-2025)
11.6.5 ThriveEarlier Detection Recent Developments
11.7 GRAIL, Inc.
11.7.1 GRAIL, Inc. Corporation Information
11.7.2 GRAIL, Inc. Business Overview
11.7.3 GRAIL, Inc. Multi-cancer Early Detection (MCED) Tests Product Features and Attributes
11.7.4 GRAIL, Inc. Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (2020-2025)
11.7.5 GRAIL, Inc. Recent Developments
11.8 CellMax life
11.8.1 CellMax life Corporation Information
11.8.2 CellMax life Business Overview
11.8.3 CellMax life Multi-cancer Early Detection (MCED) Tests Product Features and Attributes
11.8.4 CellMax life Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (2020-2025)
11.8.5 CellMax life Recent Developments
11.9 Berry Genomics
11.9.1 Berry Genomics Corporation Information
11.9.2 Berry Genomics Business Overview
11.9.3 Berry Genomics Multi-cancer Early Detection (MCED) Tests Product Features and Attributes
11.9.4 Berry Genomics Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (2020-2025)
11.9.5 Berry Genomics Recent Developments
11.10 Singlera Genomics
11.10.1 Singlera Genomics Corporation Information
11.10.2 Singlera Genomics Business Overview
11.10.3 Singlera Genomics Multi-cancer Early Detection (MCED) Tests Product Features and Attributes
11.10.4 Singlera Genomics Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
11.11 Geneseeq
11.11.1 Geneseeq Corporation Information
11.11.2 Geneseeq Business Overview
11.11.3 Geneseeq Multi-cancer Early Detection (MCED) Tests Product Features and Attributes
11.11.4 Geneseeq Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (2020-2025)
11.11.5 Geneseeq Recent Developments
11.12 BGI Genomics
11.12.1 BGI Genomics Corporation Information
11.12.2 BGI Genomics Business Overview
11.12.3 BGI Genomics Multi-cancer Early Detection (MCED) Tests Product Features and Attributes
11.12.4 BGI Genomics Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (2020-2025)
11.12.5 BGI Genomics Recent Developments
11.13 Burning Rock Biotech Limited
11.13.1 Burning Rock Biotech Limited Corporation Information
11.13.2 Burning Rock Biotech Limited Business Overview
11.13.3 Burning Rock Biotech Limited Multi-cancer Early Detection (MCED) Tests Product Features and Attributes
11.13.4 Burning Rock Biotech Limited Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (2020-2025)
11.13.5 Burning Rock Biotech Limited Recent Developments
11.14 New Horizon Health Limited
11.14.1 New Horizon Health Limited Corporation Information
11.14.2 New Horizon Health Limited Business Overview
11.14.3 New Horizon Health Limited Multi-cancer Early Detection (MCED) Tests Product Features and Attributes
11.14.4 New Horizon Health Limited Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (2020-2025)
11.14.5 New Horizon Health Limited Recent Developments
11.15 Yeasen Bio
11.15.1 Yeasen Bio Corporation Information
11.15.2 Yeasen Bio Business Overview
11.15.3 Yeasen Bio Multi-cancer Early Detection (MCED) Tests Product Features and Attributes
11.15.4 Yeasen Bio Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (2020-2025)
11.15.5 Yeasen Bio Recent Developments
11.16 Hangzhou Aoru Biotech
11.16.1 Hangzhou Aoru Biotech Corporation Information
11.16.2 Hangzhou Aoru Biotech Business Overview
11.16.3 Hangzhou Aoru Biotech Multi-cancer Early Detection (MCED) Tests Product Features and Attributes
11.16.4 Hangzhou Aoru Biotech Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (2020-2025)
11.16.5 Hangzhou Aoru Biotech Recent Developments
11.17 Amoy Diagnostics Co., Ltd.
11.17.1 Amoy Diagnostics Co., Ltd. Corporation Information
11.17.2 Amoy Diagnostics Co., Ltd. Business Overview
11.17.3 Amoy Diagnostics Co., Ltd. Multi-cancer Early Detection (MCED) Tests Product Features and Attributes
11.17.4 Amoy Diagnostics Co., Ltd. Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (2020-2025)
11.17.5 Amoy Diagnostics Co., Ltd. Recent Developments
11.18 Genetron Health
11.18.1 Genetron Health Corporation Information
11.18.2 Genetron Health Business Overview
11.18.3 Genetron Health Multi-cancer Early Detection (MCED) Tests Product Features and Attributes
11.18.4 Genetron Health Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (2020-2025)
11.18.5 Genetron Health Recent Developments
11.19 AnchorDx
11.19.1 AnchorDx Corporation Information
11.19.2 AnchorDx Business Overview
11.19.3 AnchorDx Multi-cancer Early Detection (MCED) Tests Product Features and Attributes
11.19.4 AnchorDx Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (2020-2025)
11.19.5 AnchorDx Recent Developments
11.20 Surexam Bio-Tech Co.,Ltd.
11.20.1 Surexam Bio-Tech Co.,Ltd. Corporation Information
11.20.2 Surexam Bio-Tech Co.,Ltd. Business Overview
11.20.3 Surexam Bio-Tech Co.,Ltd. Multi-cancer Early Detection (MCED) Tests Product Features and Attributes
11.20.4 Surexam Bio-Tech Co.,Ltd. Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (2020-2025)
11.20.5 Surexam Bio-Tech Co.,Ltd. Recent Developments
11.21 HaploX
11.21.1 HaploX Corporation Information
11.21.2 HaploX Business Overview
11.21.3 HaploX Multi-cancer Early Detection (MCED) Tests Product Features and Attributes
11.21.4 HaploX Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (2020-2025)
11.21.5 HaploX Recent Developments
11.22 HefeiLaierBiotechnologyCo.,Ltd
11.22.1 HefeiLaierBiotechnologyCo.,Ltd Corporation Information
11.22.2 HefeiLaierBiotechnologyCo.,Ltd Business Overview
11.22.3 HefeiLaierBiotechnologyCo.,Ltd Multi-cancer Early Detection (MCED) Tests Product Features and Attributes
11.22.4 HefeiLaierBiotechnologyCo.,Ltd Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (2020-2025)
11.22.5 HefeiLaierBiotechnologyCo.,Ltd Recent Developments
12 Multi-cancer Early Detection (MCED) TestsIndustry Chain Analysis
12.1 Multi-cancer Early Detection (MCED) Tests Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Multi-cancer Early Detection (MCED) Tests Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Multi-cancer Early Detection (MCED) Tests Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
TABLE OF FIGURES
List of Tables
Table 1. Global Multi-cancer Early Detection (MCED) Tests Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Multi-cancer Early Detection (MCED) Tests Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Multi-cancer Early Detection (MCED) Tests Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Multi-cancer Early Detection (MCED) Tests Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Multi-cancer Early Detection (MCED) Tests Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global Multi-cancer Early Detection (MCED) Tests Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global Multi-cancer Early Detection (MCED) Tests Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global Multi-cancer Early Detection (MCED) Tests by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Multi-cancer Early Detection (MCED) Tests as of 2024)
Table 11. Global Multi-cancer Early Detection (MCED) Tests Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global Multi-cancer Early Detection (MCED) Tests Companies Headquarters
Table 13. Global Multi-cancer Early Detection (MCED) Tests Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Multi-cancer Early Detection (MCED) Tests Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global Multi-cancer Early Detection (MCED) Tests Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global Multi-cancer Early Detection (MCED) Tests Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global Multi-cancer Early Detection (MCED) Tests Revenue by Application (2026-2031) & (US$ Million)
Table 21. Multi-cancer Early Detection (MCED) Tests High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Multi-cancer Early Detection (MCED) Tests Growth Accelerators and Market Barriers
Table 25. North America Multi-cancer Early Detection (MCED) Tests Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe Multi-cancer Early Detection (MCED) Tests Growth Accelerators and Market Barriers
Table 27. Europe Multi-cancer Early Detection (MCED) Tests Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific Multi-cancer Early Detection (MCED) Tests Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Multi-cancer Early Detection (MCED) Tests Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America Multi-cancer Early Detection (MCED) Tests Investment Opportunities and Key Challenges
Table 31. Central and South America Multi-cancer Early Detection (MCED) Tests Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa Multi-cancer Early Detection (MCED) Tests Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Multi-cancer Early Detection (MCED) Tests Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. Guardant Health Corporation Information
Table 35. Guardant Health Description and Major Businesses
Table 36. Guardant Health Product Features and Attributes
Table 37. Guardant Health Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. Guardant Health Revenue Proportion by Product in 2024
Table 39. Guardant Health Revenue Proportion by Application in 2024
Table 40. Guardant Health Revenue Proportion by Geographic Area in 2024
Table 41. Guardant Health Multi-cancer Early Detection (MCED) Tests SWOT Analysis
Table 42. Guardant Health Recent Developments
Table 43. Exact Sciences Corporation Information
Table 44. Exact Sciences Description and Major Businesses
Table 45. Exact Sciences Product Features and Attributes
Table 46. Exact Sciences Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Exact Sciences Revenue Proportion by Product in 2024
Table 48. Exact Sciences Revenue Proportion by Application in 2024
Table 49. Exact Sciences Revenue Proportion by Geographic Area in 2024
Table 50. Exact Sciences Multi-cancer Early Detection (MCED) Tests SWOT Analysis
Table 51. Exact Sciences Recent Developments
Table 52. Freenome Corporation Information
Table 53. Freenome Description and Major Businesses
Table 54. Freenome Product Features and Attributes
Table 55. Freenome Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. Freenome Revenue Proportion by Product in 2024
Table 57. Freenome Revenue Proportion by Application in 2024
Table 58. Freenome Revenue Proportion by Geographic Area in 2024
Table 59. Freenome Multi-cancer Early Detection (MCED) Tests SWOT Analysis
Table 60. Freenome Recent Developments
Table 61. Epiginomics AG Corporation Information
Table 62. Epiginomics AG Description and Major Businesses
Table 63. Epiginomics AG Product Features and Attributes
Table 64. Epiginomics AG Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. Epiginomics AG Revenue Proportion by Product in 2024
Table 66. Epiginomics AG Revenue Proportion by Application in 2024
Table 67. Epiginomics AG Revenue Proportion by Geographic Area in 2024
Table 68. Epiginomics AG Multi-cancer Early Detection (MCED) Tests SWOT Analysis
Table 69. Epiginomics AG Recent Developments
Table 70. Bio-techne Corporation Information
Table 71. Bio-techne Description and Major Businesses
Table 72. Bio-techne Product Features and Attributes
Table 73. Bio-techne Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. Bio-techne Revenue Proportion by Product in 2024
Table 75. Bio-techne Revenue Proportion by Application in 2024
Table 76. Bio-techne Revenue Proportion by Geographic Area in 2024
Table 77. Bio-techne Multi-cancer Early Detection (MCED) Tests SWOT Analysis
Table 78. Bio-techne Recent Developments
Table 79. ThriveEarlier Detection Corporation Information
Table 80. ThriveEarlier Detection Description and Major Businesses
Table 81. ThriveEarlier Detection Product Features and Attributes
Table 82. ThriveEarlier Detection Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. ThriveEarlier Detection Recent Developments
Table 84. GRAIL, Inc. Corporation Information
Table 85. GRAIL, Inc. Description and Major Businesses
Table 86. GRAIL, Inc. Product Features and Attributes
Table 87. GRAIL, Inc. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. GRAIL, Inc. Recent Developments
Table 89. CellMax life Corporation Information
Table 90. CellMax life Description and Major Businesses
Table 91. CellMax life Product Features and Attributes
Table 92. CellMax life Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. CellMax life Recent Developments
Table 94. Berry Genomics Corporation Information
Table 95. Berry Genomics Description and Major Businesses
Table 96. Berry Genomics Product Features and Attributes
Table 97. Berry Genomics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 98. Berry Genomics Recent Developments
Table 99. Singlera Genomics Corporation Information
Table 100. Singlera Genomics Description and Major Businesses
Table 101. Singlera Genomics Product Features and Attributes
Table 102. Singlera Genomics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. Singlera Genomics Recent Developments
Table 104. Geneseeq Corporation Information
Table 105. Geneseeq Description and Major Businesses
Table 106. Geneseeq Product Features and Attributes
Table 107. Geneseeq Revenue (US$ Million) and Gross Margin (2020-2025)
Table 108. Geneseeq Recent Developments
Table 109. BGI Genomics Corporation Information
Table 110. BGI Genomics Description and Major Businesses
Table 111. BGI Genomics Product Features and Attributes
Table 112. BGI Genomics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 113. BGI Genomics Recent Developments
Table 114. Burning Rock Biotech Limited Corporation Information
Table 115. Burning Rock Biotech Limited Description and Major Businesses
Table 116. Burning Rock Biotech Limited Product Features and Attributes
Table 117. Burning Rock Biotech Limited Revenue (US$ Million) and Gross Margin (2020-2025)
Table 118. Burning Rock Biotech Limited Recent Developments
Table 119. New Horizon Health Limited Corporation Information
Table 120. New Horizon Health Limited Description and Major Businesses
Table 121. New Horizon Health Limited Product Features and Attributes
Table 122. New Horizon Health Limited Revenue (US$ Million) and Gross Margin (2020-2025)
Table 123. New Horizon Health Limited Recent Developments
Table 124. Yeasen Bio Corporation Information
Table 125. Yeasen Bio Description and Major Businesses
Table 126. Yeasen Bio Product Features and Attributes
Table 127. Yeasen Bio Revenue (US$ Million) and Gross Margin (2020-2025)
Table 128. Yeasen Bio Recent Developments
Table 129. Hangzhou Aoru Biotech Corporation Information
Table 130. Hangzhou Aoru Biotech Description and Major Businesses
Table 131. Hangzhou Aoru Biotech Product Features and Attributes
Table 132. Hangzhou Aoru Biotech Revenue (US$ Million) and Gross Margin (2020-2025)
Table 133. Hangzhou Aoru Biotech Recent Developments
Table 134. Amoy Diagnostics Co., Ltd. Corporation Information
Table 135. Amoy Diagnostics Co., Ltd. Description and Major Businesses
Table 136. Amoy Diagnostics Co., Ltd. Product Features and Attributes
Table 137. Amoy Diagnostics Co., Ltd. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 138. Amoy Diagnostics Co., Ltd. Recent Developments
Table 139. Genetron Health Corporation Information
Table 140. Genetron Health Description and Major Businesses
Table 141. Genetron Health Product Features and Attributes
Table 142. Genetron Health Revenue (US$ Million) and Gross Margin (2020-2025)
Table 143. Genetron Health Recent Developments
Table 144. AnchorDx Corporation Information
Table 145. AnchorDx Description and Major Businesses
Table 146. AnchorDx Product Features and Attributes
Table 147. AnchorDx Revenue (US$ Million) and Gross Margin (2020-2025)
Table 148. AnchorDx Recent Developments
Table 149. Surexam Bio-Tech Co.,Ltd. Corporation Information
Table 150. Surexam Bio-Tech Co.,Ltd. Description and Major Businesses
Table 151. Surexam Bio-Tech Co.,Ltd. Product Features and Attributes
Table 152. Surexam Bio-Tech Co.,Ltd. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 153. Surexam Bio-Tech Co.,Ltd. Recent Developments
Table 154. HaploX Corporation Information
Table 155. HaploX Description and Major Businesses
Table 156. HaploX Product Features and Attributes
Table 157. HaploX Revenue (US$ Million) and Gross Margin (2020-2025)
Table 158. HaploX Recent Developments
Table 159. HefeiLaierBiotechnologyCo.,Ltd Corporation Information
Table 160. HefeiLaierBiotechnologyCo.,Ltd Description and Major Businesses
Table 161. HefeiLaierBiotechnologyCo.,Ltd Product Features and Attributes
Table 162. HefeiLaierBiotechnologyCo.,Ltd Revenue (US$ Million) and Gross Margin (2020-2025)
Table 163. HefeiLaierBiotechnologyCo.,Ltd Recent Developments
Table 164. Raw Materials Key Suppliers
Table 165. Distributors List
Table 166. Market Trends and Market Evolution
Table 167. Market Drivers and Opportunities
Table 168. Market Challenges, Risks, and Restraints
Table 169. Research Programs/Design for This Report
Table 170. Key Data Information from Secondary Sources
Table 171. Key Data Information from Primary Sources
List of Figures
Figure 1. Multi-cancer Early Detection (MCED) Tests Product Picture
Figure 2. Global Multi-cancer Early Detection (MCED) Tests Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. ctDNA Detection Product Picture
Figure 4. CTC Detection Product Picture
Figure 5. Exosome Detection Product Picture
Figure 6. Global Multi-cancer Early Detection (MCED) Tests Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 7. Medical Institutions
Figure 8. Physical Examination Centers
Figure 9. Multi-cancer Early Detection (MCED) Tests Report Years Considered
Figure 10. Global Multi-cancer Early Detection (MCED) Tests Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 11. Global Multi-cancer Early Detection (MCED) Tests Revenue (2020-2031) & (US$ Million)
Figure 12. Global Multi-cancer Early Detection (MCED) Tests Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 13. Global Multi-cancer Early Detection (MCED) Tests Revenue Market Share by Region (2020-2031)
Figure 14. Global Multi-cancer Early Detection (MCED) Tests Revenue Market Share Ranking (2024)
Figure 15. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 16. ctDNA Detection Revenue Market Share by Player in 2024
Figure 17. CTC Detection Revenue Market Share by Player in 2024
Figure 18. Exosome Detection Revenue Market Share by Player in 2024
Figure 19. Global Multi-cancer Early Detection (MCED) Tests Revenue Market Share by Type (2020-2031)
Figure 20. Global Multi-cancer Early Detection (MCED) Tests Revenue Market Share by Application (2020-2031)
Figure 21. North America Multi-cancer Early Detection (MCED) Tests Revenue YoY (2020-2031) & (US$ Million)
Figure 22. North America Top 5 Players Multi-cancer Early Detection (MCED) Tests Revenue (US$ Million) in 2024
Figure 23. North America Multi-cancer Early Detection (MCED) Tests Revenue (US$ Million) by Type (2020 - 2031)
Figure 24. North America Multi-cancer Early Detection (MCED) Tests Revenue (US$ Million) by Application (2020-2031)
Figure 25. US Multi-cancer Early Detection (MCED) Tests Revenue (2020-2031) & (US$ Million)
Figure 26. Canada Multi-cancer Early Detection (MCED) Tests Revenue (2020-2031) & (US$ Million)
Figure 27. Mexico Multi-cancer Early Detection (MCED) Tests Revenue (2020-2031) & (US$ Million)
Figure 28. Europe Multi-cancer Early Detection (MCED) Tests Revenue YoY (2020-2031) & (US$ Million)
Figure 29. Europe Top 5 Players Multi-cancer Early Detection (MCED) Tests Revenue (US$ Million) in 2024
Figure 30. Europe Multi-cancer Early Detection (MCED) Tests Revenue (US$ Million) by Type (2020-2031)
Figure 31. Europe Multi-cancer Early Detection (MCED) Tests Revenue (US$ Million) by Application (2020-2031)
Figure 32. Germany Multi-cancer Early Detection (MCED) Tests Revenue (2020-2031) & (US$ Million)
Figure 33. France Multi-cancer Early Detection (MCED) Tests Revenue (2020-2031) & (US$ Million)
Figure 34. U.K. Multi-cancer Early Detection (MCED) Tests Revenue (2020-2031) & (US$ Million)
Figure 35. Italy Multi-cancer Early Detection (MCED) Tests Revenue (2020-2031) & (US$ Million)
Figure 36. Russia Multi-cancer Early Detection (MCED) Tests Revenue (2020-2031) & (US$ Million)
Figure 37. Asia-Pacific Multi-cancer Early Detection (MCED) Tests Revenue YoY (2020-2031) & (US$ Million)
Figure 38. Asia-Pacific Top 8 Players Multi-cancer Early Detection (MCED) Tests Revenue (US$ Million) in 2024
Figure 39. Asia-Pacific Multi-cancer Early Detection (MCED) Tests Revenue (US$ Million) by Type (2020-2031)
Figure 40. Asia-Pacific Multi-cancer Early Detection (MCED) Tests Revenue (US$ Million) by Application (2020-2031)
Figure 41. Indonesia Multi-cancer Early Detection (MCED) Tests Revenue (2020-2031) & (US$ Million)
Figure 42. Japan Multi-cancer Early Detection (MCED) Tests Revenue (2020-2031) & (US$ Million)
Figure 43. South Korea Multi-cancer Early Detection (MCED) Tests Revenue (2020-2031) & (US$ Million)
Figure 44. Australia Multi-cancer Early Detection (MCED) Tests Revenue (2020-2031) & (US$ Million)
Figure 45. India Multi-cancer Early Detection (MCED) Tests Revenue (2020-2031) & (US$ Million)
Figure 46. Indonesia Multi-cancer Early Detection (MCED) Tests Revenue (2020-2031) & (US$ Million)
Figure 47. Vietnam Multi-cancer Early Detection (MCED) Tests Revenue (2020-2031) & (US$ Million)
Figure 48. Malaysia Multi-cancer Early Detection (MCED) Tests Revenue (2020-2031) & (US$ Million)
Figure 49. Philippines Multi-cancer Early Detection (MCED) Tests Revenue (2020-2031) & (US$ Million)
Figure 50. Singapore Multi-cancer Early Detection (MCED) Tests Revenue (2020-2031) & (US$ Million)
Figure 51. Central and South America Multi-cancer Early Detection (MCED) Tests Revenue YoY (2020-2031) & (US$ Million)
Figure 52. Central and South America Top 5 Players Multi-cancer Early Detection (MCED) Tests Revenue (US$ Million) in 2024
Figure 53. Central and South America Multi-cancer Early Detection (MCED) Tests Revenue (US$ Million) by Type (2020-2031)
Figure 54. Central and South America Multi-cancer Early Detection (MCED) Tests Revenue (US$ Million) by Application (2020-2031)
Figure 55. Brazil Multi-cancer Early Detection (MCED) Tests Revenue (2020-2025) & (US$ Million)
Figure 56. Argentina Multi-cancer Early Detection (MCED) Tests Revenue (2020-2025) & (US$ Million)
Figure 57. Middle East and Africa Multi-cancer Early Detection (MCED) Tests Revenue YoY (2020-2031) & (US$ Million)
Figure 58. Middle East and Africa Top 5 Players Multi-cancer Early Detection (MCED) Tests Revenue (US$ Million) in 2024
Figure 59. South America Multi-cancer Early Detection (MCED) Tests Revenue (US$ Million) by Type (2020-2031)
Figure 60. Middle East and Africa Multi-cancer Early Detection (MCED) Tests Revenue (US$ Million) by Application (2020-2031)
Figure 61. GCC Countries Multi-cancer Early Detection (MCED) Tests Revenue (2020-2025) & (US$ Million)
Figure 62. Israel Multi-cancer Early Detection (MCED) Tests Revenue (2020-2025) & (US$ Million)
Figure 63. Egypt Multi-cancer Early Detection (MCED) Tests Revenue (2020-2025) & (US$ Million)
Figure 64. South Africa Multi-cancer Early Detection (MCED) Tests Revenue (2020-2025) & (US$ Million)
Figure 65. Multi-cancer Early Detection (MCED) Tests Industry Chain Mapping
Figure 66. Channels of Distribution (Direct Vs Distribution)
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed
KEY QUESTIONS ADDRESSED BY THE REPORT
What was the global market size of Multi-cancer Early Detection (MCED) Tests in 2025?
The global market size of Multi-cancer Early Detection (MCED) Tests in 2025 was 1047 Million USD.
Which companies rank high in the global Multi-cancer Early Detection (MCED) Tests market?
What is the annual compound growth rate of the global Multi-cancer Early Detection (MCED) Tests market size from 2025 to 2031?
What was the global market size of Multi-cancer Early Detection (MCED) Tests in 2031?
Which region is expected to have the highest market share?
Related Reports
Global Multi-cancer Early Detection (MCED) Tests Market Outlook, In‑Depth Analysis & Forecast to 2032
The global Multi-cancer Early Detection (MCED) Tests market is projected to grow from US$ 1047 million in 2025 to US$ 3627 million by 2032, at a CAGR of 19.7% (2026-2032), driven by critical product segments and diverse end‑use applications.
Published Date: 2026-03-12
Pages: 162
USD 4900.00
(Single User License)
Global Multi-cancer Early Detection (MCED) Tests Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Multi-cancer Early Detection (MCED) Tests market size was US$ 1047 million in 2025 and is forecast to reach a readjusted size of US$ 3627 million by 2032 with a CAGR of 19.7% during the forecast period 2026-2032.
Published Date: 2026-03-12
Pages: 113
USD 4250.00
(Single User License)
Global Multi-cancer Early Detection (MCED) Tests Market Research Report 2026
The global Multi-cancer Early Detection (MCED) Tests market was valued at US$ 1047 million in 2025 and is anticipated to reach US$ 3627 million by 2032, at a CAGR of 19.7% from 2026 to 2032.
Published Date: 2026-03-12
Pages: 157
USD 2900.00
(Single User License)
Multi-cancer Early Detection (MCED) Tests - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Multi-cancer Early Detection (MCED) Tests was estimated to be worth US$ 1047 million in 2025 and is projected to reach US$ 3627 million, growing at a CAGR of 19.7% from 2026 to 2032.
Published Date: 2026-03-09
Pages: 143
USD 3950.00
(Single User License)
Multi-cancer Early Detection (MCED) Tests - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Multi-cancer Early Detection (MCED) Tests was estimated to be worth US$ 875 million in 2024 and is forecast to a readjusted size of US$ 3081 million by 2031 with a CAGR of 19.7% during the forecast period 2025-2031.
Published Date: 2025-07-24
Pages: 148
USD 3950.00
(Single User License)
Global Multi-cancer Early Detection (MCED) Tests Market Research Report 2025
The global market for Multi-cancer Early Detection (MCED) Tests was valued at US$ 875 million in the year 2024 and is projected to reach a revised size of US$ 3081 million by 2031, growing at a CAGR of 19.7% during the forecast period.
Published Date: 2025-07-24
Pages: 109
USD 2900.00
(Single User License)
Global Multi-cancer Early Detection (MCED) Tests Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Multi-cancer Early Detection (MCED) Tests market size was US$ 875 million in 2024 and is forecast to a readjusted size of US$ 3081 million by 2031 with a CAGR of 19.7% during the forecast period 2025-2031.
Published Date: 2025-07-24
Pages: 119
USD 4250.00
(Single User License)
Global Multi-cancer Early Detection (MCED) Tests Market Outlook, In‑Depth Analysis & Forecast to 2032
The global Multi-cancer Early Detection (MCED) Tests market is projected to grow from US$ 1047 million in 2025 to US$ 3627 million by 2032, at a CAGR of 19.7% (2026-2032), driven by critical product segments and diverse end‑use applications.
Published: 2026-03-12
Pages: 162
USD 4900.00 (Single User License)Global Multi-cancer Early Detection (MCED) Tests Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Multi-cancer Early Detection (MCED) Tests market size was US$ 1047 million in 2025 and is forecast to reach a readjusted size of US$ 3627 million by 2032 with a CAGR of 19.7% during the forecast period 2026-2032.
Published: 2026-03-12
Pages: 113
USD 4250.00 (Single User License)Global Multi-cancer Early Detection (MCED) Tests Market Research Report 2026
The global Multi-cancer Early Detection (MCED) Tests market was valued at US$ 1047 million in 2025 and is anticipated to reach US$ 3627 million by 2032, at a CAGR of 19.7% from 2026 to 2032.
Published: 2026-03-12
Pages: 157
USD 2900.00 (Single User License)Multi-cancer Early Detection (MCED) Tests - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Multi-cancer Early Detection (MCED) Tests was estimated to be worth US$ 1047 million in 2025 and is projected to reach US$ 3627 million, growing at a CAGR of 19.7% from 2026 to 2032.
Published: 2026-03-09
Pages: 143
USD 3950.00 (Single User License)Multi-cancer Early Detection (MCED) Tests - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Multi-cancer Early Detection (MCED) Tests was estimated to be worth US$ 875 million in 2024 and is forecast to a readjusted size of US$ 3081 million by 2031 with a CAGR of 19.7% during the forecast period 2025-2031.
Published: 2025-07-24
Pages: 148
USD 3950.00 (Single User License)Global Multi-cancer Early Detection (MCED) Tests Market Research Report 2025
The global market for Multi-cancer Early Detection (MCED) Tests was valued at US$ 875 million in the year 2024 and is projected to reach a revised size of US$ 3081 million by 2031, growing at a CAGR of 19.7% during the forecast period.
Published: 2025-07-24
Pages: 109
USD 2900.00 (Single User License)Global Multi-cancer Early Detection (MCED) Tests Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Multi-cancer Early Detection (MCED) Tests market size was US$ 875 million in 2024 and is forecast to a readjusted size of US$ 3081 million by 2031 with a CAGR of 19.7% during the forecast period 2025-2031.
Published: 2025-07-24
Pages: 119
USD 4250.00 (Single User License)
CHOOSE LICENSE TYPE
USD 4900.00
USD 7350.00
USD 9800.00
Add to Cart
Buy Now
HAVE A QUESTION?
General Email:
REPORT COVERAGE
DESCRIPTION
OVERVIEW
MARKET SEGMENTATION
CHAPTER OUTLINE
WHY THIS REPORT
QYRESEARCH'S STRENGTHS
TABLE OF CONTENTS
TABLE OF FIGURES
RLEATED REPORTS
INTEREST IN THIS REPORT?
Get A Free Sample
Request For Quotation
OR
NEED A CUSTOMIZED REPORT?
Customized Report
Request Sample
Pre-Order Enquiry
Add to Cart
Buy Now